SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

HC Wainwright & Co. maintained a Buy rating on SpyGlass Pharma with a $37 price target, implying 48.5% upside. The company's BIM-IOL System is in Phase 3 trials, and its acquisition of Advanced Vision Science enhances manufacturing capabilities. The stock closed at $24.92 on Oct 2.

SpyGlass Pharma (SGP) presented at Citigroup’s Biopharma Summit, outlining plans for its BIM-IOL drug-device platform. The company reported strong clinical data, with 95% of patients free of additional glaucoma therapy at three years in early trials. SpyGlass has $234 million in cash, expects Phase III trial completion in 2028, and aims for a 2029 launch. The company targets a market of 200,000 annual cataract procedures in the U.S. with glaucoma.

SpyGlass Pharma Inc. (Nasdaq: SGP) has moved to a larger headquarters in Irvine, accommodating up to 150 employees. The biopharmaceutical company, which went public in February, is focused on drug delivery solutions for chronic eye conditions. It is currently conducting Phase 3 trials for its lead product, the BIM-IOL system, with a target launch in 2029. The company's stock traded at $28.99 with a $970 million market cap, up 77% since its IPO. SpyGlass has also secured a new AMA Category III co

SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. •

Master Builders Australia forecasts Australia will miss its target of 1.2 million new homes by July 2029, with a shortfall rising to 180,200 homes (from 160,000 earlier). It also says 180,500 homes started in 2024-25, about 60,000 below the Accord’s 240,000 goal. The article highlights ASX names James Hardie, Stockland and Mirvac as potential beneficiaries.

Vodafone (VOD) raised its annual cost-savings target to £1bn by FY32 and aims to triple operating free cash flow by FY25. The company agreed to buy CK Hutchison's stake in VodafoneThree for £4.3bn, gaining full ownership of the UK's largest mobile operator. Vodafone also unveiled an £11bn, 10-year plan to build a 5G network in the UK. Societe Generale crossed a voting-rights threshold in Vodafone, filing a major-holdings notice.